Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Puma, but not noxa is essential for oligodendroglial cell death.
Epigenetic changes in patients with multiple sclerosis.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Extoxnet (extension toxicology network), 4-aminopyridine
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice.
Rituximab Use in Pediatric Central Demyelinating Disease.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
Epidemiology of Neuromyelitis Optica in the United States: A Multicenter AnalysisEpidemiology of NMO.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)

Pages